Skip to main content

A simple blood test to choose the best treatment for each patient with depression.


Major depressive disorder affects around 300M people globally and is the second leading cause of disability, with up to 14 years of life lost per patient and an annual burden of up to €170 billion to the EU. Despite numerous available drugs, 75% of patients do not receive adequate
treatment, 63% try multiple medications, and a third do not respond after two rounds of treatment. This trial-and-error approach is destructive to patients, time-consuming for physicians and expensive to health care systems. RxMine revolutionizes this process by combining innovative stem
cell technology, genetics, neurobiology, high-throughput screening and machine learning to test multiple antidepressants and screen drug effects using a patient-specific brain-in-a-dish model. RxMine identifies the optimal antidepressant for each patient and potentially reduces
hospitalizations by 89%, emergency-room visits by 71% and depression related healthcare costs by 40% with savings up to €6,000 per patient per year.


Net EU contribution
€ 2 499 000,00
126 Yigal Alon Street
6744332 Tel Aviv

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 2 499 000,00